CytoDyn Shares Exciting Results From Their Triple-Negative Breast Cancer Treatment Program with The Stock Day Podcast

Dec 05, 2019, 04:49 PM
The Stock Day Podcast welcomed CytoDyn (CYDY)(“the Company”), a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. President and CEO of the Company, Dr. Nader Pourhassan, joined Stock Day host Everett Jolly.